New COPD inhaler drug enters human safety testing
NCT ID NCT07116915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new inhaled drug called HRS-9821 in 160 people. First, healthy volunteers get a single dose to check safety. Then, people with COPD receive multiple doses. The main goal is to see what side effects occur and how the drug moves through the body. This is a safety trial, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may curb antibiotic overuse in COPD attacks
- Can pressurized breathing boost mucus clearance in lung disease?
- HIV and hidden health risks: a major study probes the link
- Can tracking early COPD reveal ways to halt its progression?
- Smart inhaler coach: can an app perfect your breathing technique?
- Could everyday supplements shield your lungs?